Kuros Biosciences AG

Research Kuros Biosciences AG (KURN) on Bullrun: market cap CHF 853.74M, P/E 123.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerKURN
ExchangeSW
CountrySwitzerland
SectorHealthcare
IndustryMedical Devices
CurrencyCHF
Market capCHF 853.74M
P/E123.2
Financial periodFY2025
RevenueUSD 146.06M
Revenue growth71.5%
Net incomeUSD 2.55M
Free cash flow-USD 2.89M
Gross margin88.6%

Valuation Snapshot

latest market cap is CHF 853.74M; P/E is 123.2.

Peer valuation comparison

Latest P/E is 123.2x versus a Healthcare sector median of 24.46x (403.7% above).

Latest P/E is 123.2x versus a Switzerland median of 20.32x (506.4% above).

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	USD 146.06M	USD 2.55M	-USD 2.89M	88.6%	n/a	USD 19.02M	USD 1.39M	USD 84.48M
FY2024	USD 85.16M	-USD 4.84M	USD 2.29M	82.1%	-0.13	USD 19.76M	USD 1.97M	USD 64.42M
FY2023	USD 33.56M	-USD 10.16M	-USD 9.17M	71.3%	-0.38	USD 14.21M	USD 2.14M	USD 56.71M
FY2022	USD 17.99M	-USD 14.60M	-USD 7.75M	59.9%	-0.43	USD 23.83M	USD 1.91M	USD 68.86M
FY2021	n/a	n/a	n/a	n/a	-0.23	n/a	n/a	n/a

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-24	CHF 853.74M	123.2	n/a	n/a

Company Brief

No company-specific news was found in the last week.

Revenue and net income both grew significantly year-over-year, with gross margins expanding to 88.6%.

Watch upcoming earnings, sector trends and broader market conditions.

Related stock research

Switzerland stocks Switzerland Healthcare stocks A-Z stock index

Other Healthcare stocks

Medartis Holding AG (1RU) MEDACTA GROUP S.A. SF-,10 (6MD) NovoCure Ltd (NVCR) Sonova H Ag (SOON) Ascom Holding AG (0QON) 26U (26U) MOLECULAR PARTNERS SF 1 (6ML) AC Immune SA (ACIU) Adc Therapeutics SA (ADCT) Addex Therapeutics Ltd (ADXN) Aevis Victoria SA (AEVS) ASCOM HLDG NA SF 0,50 (AH2N)

Frequently asked questions

What is Kuros Biosciences AG's market cap?

Kuros Biosciences AG's market capitalization is CHF 853.74M.

What is Kuros Biosciences AG's P/E ratio?

Kuros Biosciences AG's price-to-earnings (P/E) ratio is 123.2.

What does Kuros Biosciences AG do?

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio.